What is the recommended treatment for Irritable Bowel Syndrome (IBS) with constipation subtype?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 27, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of IBS with Constipation (IBS-C)

Start with soluble fiber (ispaghula/psyllium) at 3-4 g/day, building up gradually, and if symptoms persist after 4-6 weeks, escalate to linaclotide 290 mcg once daily as the most effective second-line agent for IBS-C. 1, 2, 3

First-Line Treatment: Lifestyle and Dietary Interventions

Exercise and Basic Dietary Modifications

  • Recommend regular physical exercise to all IBS-C patients as this improves global symptoms and forms the foundation of treatment 2, 3
  • Advise regular meal patterns, adequate hydration (at least 8 cups of fluid daily), and limiting caffeine, alcohol, and gas-producing foods 2, 3

Fiber Therapy

  • Begin with soluble fiber (ispaghula or psyllium) at 3-4 g/day, increasing gradually to avoid bloating and gas 1, 2, 3
  • Avoid insoluble fiber (wheat bran) entirely as it consistently worsens IBS symptoms, particularly bloating 2, 3
  • If soluble fiber fails after 4-6 weeks, add polyethylene glycol (osmotic laxative), titrating the dose according to symptoms 2

Probiotics

  • Consider a 12-week trial of probiotics for global symptoms and abdominal pain, though no specific strain can be recommended; discontinue if no improvement occurs 2, 3

Antispasmodics for Pain

  • Consider antispasmodics with anticholinergic properties (such as dicyclomine) for abdominal pain and global symptoms, but warn patients about dry mouth, visual disturbance, and dizziness 1, 2
  • Peppermint oil may be useful as an alternative antispasmodic 2

Second-Line Treatment: Secretagogues for Persistent Constipation

When first-line therapies fail after 4-6 weeks, escalate to prescription secretagogues, with linaclotide as the preferred agent. 1, 2

Linaclotide (Preferred Second-Line Agent)

  • Linaclotide 290 mcg once daily is the most efficacious secretagogue available for IBS-C, with strong recommendation and high-quality evidence 1, 2
  • Linaclotide significantly improves abdominal pain, bloating, stool frequency, and stool consistency over 26 weeks of treatment 4
  • Warn patients that diarrhea is a common side effect (4.5% discontinuation rate) 1, 4

Lubiprostone (Alternative Second-Line Agent)

  • Lubiprostone 8 mcg twice daily with food is an effective alternative if linaclotide is not tolerated 1, 2, 5
  • This secretagogue is less likely to cause diarrhea than linaclotide 1
  • Warn patients that nausea is a frequent side effect; taking with food and water reduces nausea 1, 5
  • Dose adjustment required for hepatic impairment: 8 mcg once daily for severe impairment (Child-Pugh Class C) 5
  • Contraindicated in patients with known or suspected mechanical gastrointestinal obstruction 5

Other Secretagogues (Where Available)

  • Plecanatide is an efficacious alternative, though diarrhea is equally common as with linaclotide 1
  • Tenapanor is effective with strong evidence, but diarrhea is a frequent side effect 1
  • Tegaserod is effective but unavailable outside the USA 1

Third-Line Treatment: Neuromodulators for Refractory Pain

When abdominal pain persists despite adequate treatment of constipation, add tricyclic antidepressants (TCAs) as gut-brain neuromodulators. 2, 3

Tricyclic Antidepressants

  • Start amitriptyline 10 mg once daily at bedtime, titrating slowly to 30-50 mg daily 2, 3
  • Explain to patients that TCAs are used as gut-brain neuromodulators, not for depression 3
  • Use cautiously in IBS-C as TCAs may worsen constipation; ensure adequate laxative therapy is in place 2
  • Continue for at least 6 months if the patient reports symptomatic response 2

Selective Serotonin Reuptake Inhibitors (SSRIs)

  • SSRIs are effective alternatives when TCAs are not tolerated or worsen constipation 2, 3
  • SSRIs have a lower side effect profile compared to TCAs 2

Fourth-Line Treatment: Psychological Therapies

Consider psychological therapies when symptoms persist despite 12 months of pharmacological treatment. 1, 2, 3

  • IBS-specific cognitive behavioral therapy (CBT) is effective for global symptoms with strong recommendation 1, 2, 3
  • Gut-directed hypnotherapy is effective for global symptoms with strong recommendation 1, 2, 3
  • Referral can be made earlier based on patient preference if accessible locally 1

Dietary Therapy: Low-FODMAP Diet

  • If symptoms persist after first-line fiber therapy, consider a low-FODMAP diet as second-line dietary therapy 2, 3
  • This must be supervised by a trained dietitian with planned reintroduction of foods according to tolerance 2, 3
  • Do not recommend gluten-free diets unless celiac disease has been confirmed 2, 3
  • Never use IgG antibody-based food elimination diets as they lack evidence and may lead to unnecessary dietary restrictions 2, 3

Critical Pitfalls to Avoid

  • Never start with insoluble fiber (wheat bran) as it will worsen symptoms, particularly bloating 2, 3
  • Avoid extensive investigations once IBS is diagnosed based on symptom criteria in the absence of alarm features 2, 3
  • Do not promise complete symptom resolution; the goal is symptom relief and improved quality of life 2
  • Review efficacy after 3 months of treatment and discontinue if no response 2
  • Recognize frequent comorbidity with mental health disorders and consider referral when necessary 2

When to Refer to Gastroenterology

  • Refer when there is diagnostic doubt, severe symptoms, or symptoms refractory to first-line treatments after 12 weeks 3
  • Consider referral for severe or refractory IBS symptoms with review of diagnosis and consideration of further targeted investigation 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Tratamiento del Síndrome de Intestino Irritable

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Initial Treatment of Irritable Bowel Syndrome

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.